Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.38 EUR | -1.81% | +1.60% | -14.03% |
04-22 | Nicox: cash position of 9.1 million euros at the end of March | CF |
02-28 | Nicox, BlackRock Sign Deal for Debt Restructuring | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.03% | 20.47M | - | ||
+5.48% | 71.19B | A | ||
+12.55% | 9.3B | A- | ||
-13.75% | 5.01B | A- | ||
+42.38% | 4.47B | - | ||
+4.51% | 3.96B | B- | ||
+21.10% | 2.44B | B | ||
-19.05% | 2.41B | C- | ||
-28.72% | 2.23B | - | ||
+11.13% | 2.02B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALCOX Stock
- Ratings Nicox SA